The 0.25 mg setting that most people pass through in their first month as an adjustment dose simply becomes the dose you stay on
For patients who are uncomfortable with needles or have difficulty administering injections themselves, Rybelsus may be a more attractive option
Cancer Res 2014;74:658997
Yang D, Liu Q, Xu Q, Zheng L, Zhang S, Lu S, Xiao G, Zhao M
Semaglutide has previously been shown in the SELECT trial to significantly reduce major adverse cardiovascular events in overweight/obese patients with known heart disease but without diabetes, Chen explained
According to the Summary of Product Characteristics (SmPC), no dose adjustment is required based on renal or hepatic impairment, though clinical experience is limited in patients with severe renal impairment or end-stage kidney disease